IMARC Services Private Limited, located at 134 N 4th St. Brooklyn, NY 11249, USA, has published a market research report titled: " Japan's Oral Antidiabetic Drugs Market: Industry Trends, Share, Size, Growth, Opportunities, Forecast 2024-2032 ".
Market outlook 2024-2032
- Japan Oral Antidiabetic Drugs Market Growth (2024-2032): The Japanese oral market is projected to exhibit a growth rate (CAGR) of 4.33% during 2024-2032.
Request sample report : https://www.imarcgroup.com/japan-oral-anti-diabetic-drug-market/requestsample
Increasing public awareness about the risks associated with diabetes and the importance of early intervention is driving market growth in Japan. Government-led awareness campaigns and efforts by medical institutions and pharmaceutical companies are contributing to improved understanding and early diagnosis of diabetes. As awareness increases, more individuals are seeking treatment, including oral antidiabetic medications, to effectively manage their condition. Japan boasts a strong medical infrastructure and universal health insurance. Access to medical services, including some prescription drugs such as oral antidiabetic drugs, is relatively easy for people. This accessibility facilitates the diagnosis and treatment of diabetes.
Check out the complete report, including table of contents. : https://www.imarcgroup.com/japan-oral-anti-diabetic-drug-market
Report highlights and segmentation
Reports are divided into the following categories:
By medicine:
- biguanide
- metformin
- α-glucosidase inhibitor
- Dopamine D2 receptor agonist
- Bromocriptine
- SGLT-2 inhibitor
- Canagliflozin (Canagliflozin)
- Jardiance (empagliflozin)
- Farxiga/Farxiga (dapagliflozin)
- Sagrat (ipragliflozin)
- DPP-4 inhibitor
- Onglyza (saxagliptin)
- Tragenta (linagliptin)
- Vipidia/Nesina (Alogliptin)
- Galvus (Vildagliptin)
- Sulfonylurea
- Meglitinides
Based on this drug, the market is divided into biguanides (metformin), alpha-glucosidase inhibitors, dopamine D2 receptor agonists (bromocriptine), SGLT-2 inhibitors (Invokana (canagliflozin), Jardiance (empagliflozin), Falsiga /Forxiga (dapagliflozin), Sugrat (ipragliflozin), DPP-4 inhibitors (Onglyza (saxagliptin), Tragenta (linagliptin), Bipidia/Nesina (alogliptin), Galvas (vildagliptin)), sulfonylureas, and meglitinides. I am.
Regional market breakdown:
- Kanto Region
- Kansai/Kinki Region
- Sentara/ Chubu Legion
- Kyushu Okinawa Region
- Tohoku Region
- Chugoku Region
- Hokkaido Legion
- Shikoku Legion
If you require specific information that is not currently within the scope of the report, it will be provided as part of your customization.
Company Profile:
IMARC Group is a leading market research firm providing business strategy and market research worldwide. We partner with clients across all sectors and geographies to identify their highest-value opportunities, address their most important challenges, and transform their businesses.
IMARC's information products include key market, scientific, economic, and technological developments for business leaders in pharmaceutical, industrial, and high-tech organizations. Market forecasting and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology, new processing methods and more are at the top of the company's expertise.
The services we provide include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team of experienced researchers and analysts from a variety of industries is dedicated to providing high-quality data and insights to our customers, from small businesses to Fortune 1000 companies. .
inquiry:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Email: sales@imarcgroup.com
Follow us on Twitter: @imarcglobal
LinkedIn: https://www.linkedin.com/company/imarc-group/